| ABSTRACT Objective: To explore the clinical efficacy of bailing capsule for treating patients with asthma COPD overlap(ACO). Methods:61 patients with ACO were collected in the respiratory department and randomly divided into control group (30 cases) and observation group (31 cases). While the control group was given conventional treatment, the observation group was given bailing capsule on the basis of conventional treatment, comparing the acute exacerbation frequency and steady duration, pulmonary ventilation function such as FEV1% Pred, FEV1 / FVC, diurnal PEF variability, classification and proportion of sputum induced inflammatory cells, the level of IL 6, IL 4, TNF α in blood serum, SGRQ scores and 6 minutes walking distance(6 MWD). Results:After one year of follow up, compared with the control group, the acute exacerbation frequency of the observation group decreased significantly, and the steady duration increased significantly (P<0.05); diurnal PEF variability of the observation group decreased after treatment than before (P<0.05). After treatment, the neutrophils and eosinophils of sputum induced decreased, macrophages increased in both two groups (P<0.05); Compared with the control group, the neutrophils and eosinophils were lower and the macrophages were much higher than the observation group (P<0.05); The IL 4, IL 6 and TNF α in both groups decreased after treatment (P<0.05), SGRQ scores decreased and the 6 MWD increased after treatment (P<0.05). There was no difference between two groups (P>0.05). Conclusion:Bailing capsule could improve the clinical indexes and the quality of life of patients with ACO as an adjuvant therapy. |
